SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
HuMAB companies
An SI Board Since May 2000
Posts SubjectMarks Bans
1022 55 0
Emcee:  nigel bates Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
722Cell Genesys Reports Potential Breakthrough in Antibody Production Technology TuIcebrg-4/19/2005
721Therapeutic Antibody Companies EvoGenix & Absalus Combine Operations Tuesdaynigel bates-4/5/2005
720...publication of data that for the first time demonstrates that soluble, high anigel bates-3/1/2005
719BioInvent presents data indicating no development of resistance in HIV project nigel bates-2/24/2005
718Nat Biotechnol. 2005 Feb 20; [Epub ahead of print] Generation of high-affinityscaram(o)uche-2/23/2005
717Seattle Genetics and CuraGen Expand Antibody-Drug Conjugate Collaboration TuesdaIcebrg-2/15/2005
716Morphosys "achieves profitability"... Message 21045368nigel bates-2/14/2005
715way back, when we were producing human MAbs from EBV transformants..... Kyowascaram(o)uche-2/4/2005
714BioWa Announces New Generation Of Technology: Potelligent RNAi PRINCETON, N.J./Icebrg-2/4/2005
713First MorphoSys-Generated Antibody Enters Clinical Trials in Partnered Program TIcebrg-2/1/2005
712Acquisitions positions MorphoSys within top 5 21/01/2005 - Biotechnology companIcebrg-1/21/2005
711InNexus and Epitomics enter into a Co-Development Agreement for Therapeutic TranIcebrg-1/12/2005
710Raven biotechnologies Initiates Phase 1/2a Trial of RAV12 in Gastrointestinal CaIcebrg-1/11/2005
709Scancell Signs New Agreement with Biovation to DeImmunise SC101 NOTTINGHAM, EngIcebrg-1/11/2005
708Antibodies Derived from Dyax Library Enter Clinical Trials at ImClone Systems CIcebrg-1/11/2005
707Merck and Diversa to Collaborate on Development of Novel Therapeutic Antibody TuIcebrg-1/11/2005
706Xencor and Chugai Initiate Partnership for Optimized Antibodies Monday January 1nigel bates-1/10/2005
705Biocon cancer drug study results in May Friday, 31 December , 2004, 13:39 BangaIcebrg-12/31/2004
704MorphoSys extends Centocor deal, gets more funds Thu Dec 23, 2004 02:07 AM ET FIcebrg-12/23/2004
703Serono and Micromet to Collaborate in Development and Commercialization of Novelnigel bates-12/7/2004
702Xencor and Genentech to Collaborate to Develop Next-Generation Antibody TherapeuIcebrg-12/1/2004
701Cambridge Antibody Technology and AstraZeneca Announce Major Strategic Alliance Icebrg-11/22/2004
700YM BioSciences Announces Start of European TheraCIM Trial Thursday November 18, Icebrg-11/20/2004
699Rochester's Biotech Business Expands [Some local reporting on the Vaccinex Icebrg-11/20/2004
698<i>Will an Indian manufacturer of protein drugs have any major advantages nigel bates-11/18/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News